Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5

被引:52
作者
Camarda, Valeria [1 ,2 ,3 ]
Fischetti, Carmela [1 ,2 ,3 ]
Anzellotti, Nicholas [1 ,2 ,3 ]
Molinari, Paola [4 ]
Ambrosio, Caterina [4 ]
Kostenis, Evi [5 ]
Regoli, Domenico [1 ,2 ,3 ]
Trapella, Claudio [6 ,7 ]
Guerrini, Remo [6 ,7 ]
Severo, Salvadori [6 ,7 ]
Calo, Girolamo [1 ,2 ,3 ]
机构
[1] Univ Ferrara, Dept Expt & Clin Med, Pharmacol Sect, I-44100 Ferrara, Italy
[2] Univ Ferrara, Ctr Neurosci, I-44100 Ferrara, Italy
[3] Natl Inst Neurosci, I-44100 Ferrara, Italy
[4] ISS, Dept Pharmacol, Rome, Italy
[5] Inst Pharmaceut Biol, Bonn, Germany
[6] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy
[7] Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy
关键词
Nociceptin/orphanin FQ; NOP receptor; Receptor pharmacological profile; CHO cells; Chimeric G alpha(qi5) protein; Calcium mobilization assay; NOCICEPTIN/ORPHANIN FQ RECEPTOR; IN-VITRO CHARACTERIZATION; SELECTIVE ANTAGONIST; PARTIAL AGONIST; ORL1; RECEPTOR; HIGH-AFFINITY; AMINO-ACIDS; POTENT; J-113397; PEPTIDE;
D O I
10.1007/s00210-009-0396-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, the G alpha(qi5) protein was used to force the human nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor to signal through the Ca2+ pathway in CHO cells. [Ca2+](i) levels were monitored using the fluorometer FlexStation II and the Ca2+ dye Fluo 4 AM. Concentration response curves were generated with a panel of full and partial agonists, while NOP antagonists were assessed in inhibition-response curves. The following rank order of potency of antagonists was measured: SB - 612111 > J - 113397 Trap - 101 >= UFP - 101 > [Nphe(1)]N/OF Q(1 - 13)NH2 >> naloxone, which is superimposable to literature findings. The rank order of potency of full and partial agonists is also similar to that obtained in previous studies with the exception of a panel of ligands (UFP-112, Ro 64-6198, ZP120, UFP-113) whose potency was relatively low in the G alpha(qi5)-NOP receptor calcium assay. Interestingly, these NOP ligands are characterized by slow kinetic of interaction with the NOP receptor, as demonstrated by bioassay experiments. These results demonstrated that the FlexStation II-G alpha(qi5)-NOP receptor calcium assay represents an adequate and useful screening for NOP receptor ligands, particularly for antagonists.
引用
收藏
页码:599 / 607
页数:9
相关论文
共 42 条
  • [1] Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Cα,α-dialkylated amino acids
    Arduin, Marika
    Spagnolo, Barbara
    Calo, Girolamo
    Guerrini, Remo
    Carra, Giacomo
    Fischetti, Carmela
    Trapella, Claudio
    Marzola, Erika
    McDonald, John
    Lambert, David G.
    Regoli, Domenico
    Salvadori, Severo
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (13) : 4434 - 4443
  • [2] Berger H, 2000, J PHARMACOL EXP THER, V294, P428
  • [3] In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist
    Bigoni, R
    Calo', G
    Rizzi, A
    Guerrini, R
    De Risi, C
    Hashimoto, Y
    Hashiba, E
    Lambert, DG
    Regoli, D
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 361 (05) : 565 - 568
  • [4] [Phe1ψ(CH2-NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor
    Butour, JL
    Moisand, C
    Mollereau, C
    Meunier, JC
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 349 (01) : R5 - R6
  • [5] Calo G, 2005, CNS DRUG REV, V11, P97
  • [6] The mouse vas deferens: A pharmacological preparation sensitive to nociceptin
    Calo, G
    Rizzi, A
    Bogoni, G
    Neugebauer, V
    Salvadori, S
    Guerrini, R
    Bianchi, C
    Regoli, D
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 311 (01) : R3 - R5
  • [7] [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor
    Calo, G
    Rizzi, A
    Rizzi, D
    Bigoni, R
    Guerrini, R
    Marzola, G
    Marti, M
    McDonald, J
    Morari, M
    Lambert, DG
    Salvadori, S
    Regoli, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (02) : 303 - 311
  • [8] Characterization of [Nphe1]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist
    Calo', G
    Guerrini, R
    Bigoni, R
    Rizzi, A
    Marzola, G
    Okawa, H
    Bianchi, C
    Lambert, DG
    Salvadori, S
    Regoli, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (06) : 1183 - 1193
  • [9] Pharmacology of nociceptin and its receptor: a novel therapeutic target
    Calo, G
    Guerrini, R
    Rizzi, A
    Salvadori, S
    Regoli, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (07) : 1261 - 1283
  • [10] [(pF)Phe4, Arg14, Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor
    Carrà, G
    Rizzi, A
    Guerrini, R
    Barnes, TA
    McDonald, J
    Hebbes, CP
    Mela, F
    Kenigs, VA
    Marzola, G
    Rizzi, D
    Gavioli, E
    Zucchini, S
    Regoli, D
    Morari, M
    Salvadori, S
    Rowbotham, DJ
    Lambert, DG
    Kapusta, DR
    Calo, G
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03) : 1114 - 1123